Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 14, Issue 18, 2008, Pages 2797-2801

  Ishikawa, Toru ^a  

^a Saiseikai Niigata Second Hospital   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Chemotherapy; Enteric coated tegafur uracil; Lung metastasis; Portal vein tumor thrombus; Tumor dormancy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; TEGAFUR; UFT; UFT E; URACIL;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASCITES; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; ENTERIC COATED TABLET; GASTROINTESTINAL DISEASE; HEPATIC ENCEPHALOPATHY; HUMAN; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER METASTASIS; LIVER SURGERY; LUNG METASTASIS; MONOTHERAPY; MULTIPLE CANCER; NAUSEA; PATIENT COMPLIANCE; PIGMENT DISORDER; PORTAL VEIN THROMBOSIS; PROGNOSIS; REVIEW; STOMACH CANCER; STOMATITIS; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; VOMITING;

EID: 48049083753     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2797     Document Type: Review

References (32)

1. Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, Asakura H. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001; 16: 1274-1281
2. Heidelberger C, Chaudhuri NK, Dannerberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666
3. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237
4. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14: 3085-3096
5. Hiller SA, Zhuk RA, Lidak Mj, Zidermane AA. Br Patent 1968; 1: 391-395
6. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978; 69: 763-772
7. Takahashi H, Kamano T. [Clinical results of UFT enteric-coated granule therapy under cooperative study (phase II study). Tokyo Cancer Chemotherapy Cooperative Study Group] Gan To Kagaku Ryoho 1990; 17: 2043-2049
8. Kikuchi K, Wakui A. [Cooperative research of UFT E phase II study. Cooperative Study Group of UFT E in Tohoku Area] Gan To Kagaku Ryoho 1990; 17: 2183-2190
9. Heidelberger C, Kaldor G, Mukherjee KL, Danneberg PB. Studies on fluorinated pyrimidines. XI. In vitro studies on tumor resistance. Cancer Res 1960; 20: 903-909
10. Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem 1961; 236: 3006-3013
11. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405-5412
12. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237
13. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, Yamada Y. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999; 5: 2185-2191
14. Basaki Y, Yonekura K, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Aoyagi K, Yamada Y. [Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice] Gan To Kagaku Ryoho 2000; 27: 93-98
15. Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36: 237-244
16. Ishikawa T, Ichida T, Ishimoto Y, Yokoyama J, Nomoto M, Ebe Y, Usuda H, Naito M, Asakura H. Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. Am J Gastroenterol 1999; 94: 1682-1685
17. Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, Uehara K, Inayoshi J, Yokoyama J, Ishimoto Y, Asakura H. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16: 452-459
18. Takahashi Y, Nishioka K. Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 1995; 87: 1262-1263
19. Kusunoki M, Yanagi H, Kotera H, Noda M, Yamamura T. Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int J Oncol 1998; 13: 653-657
20. Kusunoki M, Yanagi H, Noda M, Yamamura T. The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep 1999; 6: 547-552
21. Ishikawa T, Sato S, Matsuzawa J, Mita Y, Matsui S, Tashiro K, Tashiro S, Matsuki H. [A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with angiotensin-II and administration of tegafur/uracil] Gan To Kagaku Ryoho 2001; 28: 521-525
22. Ishikawa T, Mita Y, Kobayashi M, Tashiro K, Tashiro S, Matsuki H. [A case of nonresectable scirrhous type gastric cancer treated by hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy] Gan To Kagaku Ryoho 2001; 28: 1137-1140
23. Ishikawa T, Nomura K, Baba Y, Hayashi S, Oota H, Yoshida T, Kamimura T. [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy] Gan To Kagaku Ryoho 2003; 30: 1151-1155
24. Ishikawa T, Mizuno K, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. [A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy] Gan To Kagaku Ryoho 2005; 32: 523-527
25. Ishikawa T, Mizuno K, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. [Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination] Gan To Kagaku Ryoho 2005; 32: 469-472
26. Ishikawa T, Mizuno K, Watanabe K, Baba Y, Oota H, Yoshida T, Kamimura T. [A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/ uracil] Gan To Kagaku Ryoho 2004; 31: 1555-1558
27. Ishikawa T, Ishikawa N, Oota H, Yoshida T, Honma A, Kamimura T, Takeda K, Ishikawa N, Ozaki T. [A case of common bile duct cancer responding to MMC leucovorin, 5-FU, and UFT combination chemotherapy and radiation] Gan To Kagaku Ryoho 1996; 23: 773-777
28. Takayasu Y. [Hepatic arterial infusion chemotherapy for hepatocellular carcinoma by EEP regimen] Nippon Rinsho 2001; 59 Suppl 6]: 624-628
29. Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007; 13: 5465-5470
30. Ishikawa T, Ichida T, Yokoyama J, Matsuda Y, Watanabe T, Asakura H. Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. J Gastroenterol Hepatol 2004; 19: 1423-1426
31. Ohyama M, Matsumura. M, Katsuta K, Nobori T, Matsuyama H, Fukami K, Kiyota R, Yano H, Shima T, Ogawa K. [A comparative study of UFT enteric-coated granules with UFT capsules on the occurrence of side effects in patients with head and neck cancers - a special attention to the upper gastrointestinal tract disorders] Gan To Kagaku Ryoho 1990; 17: 1211-1216
32. Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, Kumada H. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995; 18: 204-210